Novo Nordisk hails ‘remarkable’ weight loss result for dual-acting oral drug in early trial
Novo Nordisk has lifted the lid on a phase 1 trial of its oral amylin and GLP-1 receptor co-agonist, linking the candidate to 13.1% weight loss after 12 weeks—and highlighting the potential for further reductions in longer trials.
Obesity drugs in kindergarten? Novo Nordisk GLP-1 drug works for kids as young as 6, study finds.
Amid an ongoing debate over what role, if any, GLP-1 medications should play in treating children who are still in elementary school, researchers have concluded that a Novo Nordisk obesity drug may be safe and effective for kids as young as 6 years of age.
Novo Nordisk's New Weight Loss Drug Shows Ominous Psychiatric Side Effects
Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to its trial results, it has some pretty freaky side effects. As Fierce Biotech reports,
Novo Nordisk’s amylin pill leads to substantial weight loss in early study
Novo Nordisk reported that its new obesity pill led to substantial weight loss in an early study, boosting the company’s pipeline of next-generation candidates.
Novo Shares Fall on Safety Data for New Weight-Loss Drug
Shares of Novo Nordisk A/S fell after the Danish drugmaker reported mixed safety data on one of its next-generation weight-loss drugs.
Novo Nordisk shares drop nearly 5% on disappointing obesity pill data
Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market expectations.
Novo Nordisk Sinks on Obesity Drug Study's Disappointing Results
Key Takeaways Novo Nordisk's U.S.-listed shares lost ground Friday after a Phase 2a trial of the pharmaceutical firm’s latest obesity treatment showed less effectiveness in higher doses.Based on the results,
Viking, Structure, Terns benefiting from disappointing Novo Nordisk weight loss data
Structure Therapeutics (NASDAQ:GPCR), and Terns Pharmaceuticals (NASDAQ:TERN), which are all developing oral pills as weight loss treatments, are trading higher Friday following disappointing results from a rival Novo Nordisk (NVO) drug.
Novo Nordisk stock tumbled over the latest results for its experimental weight loss pill
Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that works differently than its already-popular weight loss drug Wegovy.
This Small-Cap Stock Has a Promising GLP-1 Drug That Could Rival Novo Nordisk's and Eli Lilly's Weight Loss Treatments
In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...
GLP-1 drugs could help prevent 34,000 heart attacks and strokes in the US each year, research suggests
Certain blockbuster weight-loss drugs have been found to protect the heart in significant ways, and new research suggests ...
Novo Nordisk: The Street Is Not Seeing The Growth Acceleration Potential
Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...
STAT2d
Long-overlooked scientist shares Lasker Award with other GLP-1 researchers
GLP-1 based drugs are transforming the treatment of obesity and opening up new avenues for addressing heart disease, ...
CNN3d
GLP-1 drugs could help prevent 34,000 heart attacks and strokes in the US each year, research suggests
Wegovy is part of a class of drugs called GLP-1 receptor agonists, and its active ingredient, semaglutide, is also approved to treat type 2 diabetes as Ozempic. Novo Nordisk’s trial was limited ...
Multiple Strong Catalysts And Attractive Valuation Make Novo Nordisk A Buy
Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.